Seo Salimi

Seo Salimi is a partner in Goodwin's Life Science group. His practice focuses on representing life science companies and underwriting syndicates in public and private capital markets transactions such as initial public offerings, follow-on offerings and private placements. Seo has extensive experience in cross-border financing transactions and has represented numerous issuers and underwriters in complex dual listings and cross border initial public offerings and follow-on financings. Seo is a trusted advisor to both public and private companies in their capital raising strategy, ongoing corporate matters, including SEC compliance and corporate governance.

A selection of Seo’s recent representations include:

Domestic Representations

• Karuna Therapeutics, Inc. in its initial public offering and follow-on offerings, aggregating over $1.5 billion in proceeds
• HOOKIPA Pharma Inc. in its initial public offering and follow-on offerings, aggregating over $200 million in proceeds
• Goldman Sachs & Co. LLC and other underwriters in the initial public offering and follow-on offerings by Arvinas, Inc., aggregating over $600 million in proceeds
• Goldman Sachs & Co. LLC and other underwriters in the $145 million initial public offering by Omega Therapeutics, Inc.
• Goldman Sachs & Co. LLC and other underwriters in the initial public offering and follow-on offering by Taysha Gene Therapies, aggregating over $200 million in proceeds
• Goldman Sachs & Co. LLC and the other underwriters in the $145 million initial public offering by Harmony Biosciences Holdings, Inc.
• Goldman Sachs & Co. LLC and Morgan Stanley and other underwriters in the $135 million initial public offering by Pandion Therapeutics
• Goldman Sachs & Co. LLC and JP Morgan as underwriters in over $1.5 billion of equity offerings by Sarepta Therapeutics, Inc.
• Goldman Sachs & Co. LLC and JP Morgan as initial purchasers in over $1.5 billion of 144A offerings by Sarepta Therapeutics, Inc.
• Goldman Sachs & Co. LLC and other underwriters in over $250 million in follow-on offerings by Krystal Biotech, Inc.
• Goldman Sachs & Co. LLC and other underwriters in the $140 million follow-on public offering by Syndax Pharmaceuticals, Inc.
• Goldman Sachs & Co. LLC and JP Morgan as underwriters in the $610 million initial public offering by Switch, Inc.
• J.P. Morgan Securities and other underwriter in the $75 million follow-on offering by Precigen, Inc. 
• SVB Securities and other underwriters in the $50 million follow-on offering by scPharmaceuticals
• Citigroup and other underwriters in the $150 million initial public offering by Sensei Biotherapeutics, Inc.
• Citigroup and other underwriters in the $135 million initial public offering by Decibel Therapeutics, Inc.

Cross-Border Representations

• CRISPR Therapeutics AG in its initial public offering and follow-on offerings, aggregating over $1.0 billion in proceeds (Country of Issuer: Switzerland)
• Achilles Therapeutics plc is its $175 million initial public offering (Country of Issuer: United Kingdom)
• Fusion Pharmaceuticals Inc. in its $210 million initial public offering (Country of Issuer: Canada)
• Ablynx NV in its $230 million initial public offering (Country of Issuer: Belgium)
• Goldman Sachs & Co. LLC and other underwriters in the $510 million initial public offering by Exscientia plc (Country of Issuer: United Kingdom)
• Goldman Sachs & Co. LLC and other underwriters in the $125 million initial public offering by Ambrx, Inc. (Country of Issuer: Cayman Islands)
• Goldman Sachs & Co. LLC and other underwriters in the $107 million initial public offering by Valneva SE (Country of Issuer: France)
• Morgan Stanley, Goldman Sachs & Co. LLC and other underwriters in the initial public offering and follow-on offering by Repare Therapeutics Inc., aggregating over $300 million in proceeds (Country of Issuer: Canada)
• Goldman Sachs & Co. LLC, Morgan Stanley and other underwriters in over $$500 million of equity offerings by DBV Technologies (Country of Issuer: France)
• Citigroup and other underwriters in the $130 million initial public offering by Opthea Ltd. (Country of Issuer: Australia)
• Underwriting syndicates in the initial public offering and follow-on offering by AC Immune SA (Country of Issuer: Switzerland)
• SVB Securities LLC in the $140 million public offering by Aurinia Pharmaceuticals Inc. (Country of Issuer: Canada)
• Cantor Fitzgerald & Co. as placement agent in a registered direct offering by Evogene Ltd. (Country of Issuer: Israel)

Prior to joining Goodwin, Seo was an associate at Latham & Watkins LLP and later served as the general counsel of a NASDAQ listed company.

Seo is recognized by The Legal 500 United States as a “Next Generation Partner” in the Capital Markets: Equity category, and is commended by the publication in the following terms: “[Seo] Salimi is committed, hard-working and driven; his ability to manage across his team, both up and down, as well as his interactions with counsel from the other party makes [Seo] invaluable.”

In 2020, Seo was recognized by IFLR1000 in the “Corporate and M&A” category and nominated by LMG Life Sciences for the “US Rising Star – Financial & Corporate” award.

Seo’s recent publications include:

• Author, “How the biotech capital markets are faring in the time of COVID-19,” MedCity News, August 2020
• Author, “Capital Markets in the Time of Pandemic – Second Quarter Biotech Update,” Goodwin Insights, July 2020
• Co-Author, “Life Science Cos. Navigate Dicey Path To Public Markets,” Law360, April 2020